Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis.

Kaplan-Lefko PJ, Sutherland BW, Evangelou AI, Hadsell DL, Barrios RJ, Foster BA, Demayo F, Greenberg NM

Oncogene19 Nov 2007Cited by 25 (Europe PMC)

PMID18026134DOI10.1038/sj.onc.1210943PepBankPUB-18026134

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

01AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
In transgenic mice, epithelial IGF-1(des) expression caused hyperplastic prostate lesions in all mice.
In plain wordsIn mice, prostate expression of the IGF-1(des) gene caused excess prostate tissue growth.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
IncreaseProstate hyperplastic lesions
Study
mousen: not reported in source
PB-Des transgenic mice
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Expression of IGF-1(des) was sufficient to cause hyperplastic lesions in all mice, however the well-differentiated lesions did not progress to adenocarcinoma within a year.
1 context sentence(design, population, supporting numbers)
Summary · context
To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1(des) in prostate epithelial cells.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1802613401
02AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
In transgenic mice, IGF-1(des)-associated well-differentiated lesions did not progress to adenocarcinoma within a year.
In plain wordsIn mice, lesions associated with IGF-1(des) gene expression did not progress to adenocarcinoma within a year.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
No significant changeProgression to adenocarcinoma
Study
mousen: not reported in source
PB-Des transgenic mice
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Expression of IGF-1(des) was sufficient to cause hyperplastic lesions in all mice, however the well-differentiated lesions did not progress to adenocarcinoma within a year.
1 context sentence(design, population, supporting numbers)
Summary · context
To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1(des) in prostate epithelial cells.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1802613402
03AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
In young bigenic mice, crossing PB-Des mice with a prostate cancer model delayed progression of organ-confined tumors.
In plain wordsIn young mice, adding prostate IGF-1(des) gene expression to a cancer model delayed localized tumor progression.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
DecreaseOrgan-confined tumor progression
Study
mousen: not reported in source
Young bigenic mice from crossing PB-Des mice with a prostate cancer model
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Remarkably, crossing the PB-Des mice to an established model of prostate cancer delayed progression of organ-confined tumors and emergence of metastatic lesions in young mice.
1 context sentence(design, population, supporting numbers)
Summary · context
To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1(des) in prostate epithelial cells.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1802613403
04AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
In young bigenic mice, crossing PB-Des mice with a prostate cancer model delayed emergence of metastatic lesions.
In plain wordsIn young mice, adding prostate IGF-1(des) gene expression to a cancer model delayed the appearance of cancer spread.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
DecreaseEmergence of metastatic lesions
Study
mousen: not reported in source
Young bigenic mice from crossing PB-Des mice with a prostate cancer model
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Remarkably, crossing the PB-Des mice to an established model of prostate cancer delayed progression of organ-confined tumors and emergence of metastatic lesions in young mice.
1 context sentence(design, population, supporting numbers)
Summary · context
To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1(des) in prostate epithelial cells.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1802613404
05AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
In old bigenic mice, investigators did not detect IGF-1(des) in poorly differentiated primary tumors or metastatic lesions.
In plain wordsIn old mice, researchers did not detect IGF-1(des) in poorly differentiated tumors or cancer deposits.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
Direction not reportedIGF-1(des) detection in tumors and metastases
Study
mousen: not reported in source
Old bigenic mice from crossing PB-Des mice with a prostate cancer model
Outcome group
Tumor growth · Cancer
Source sentences
Summary
While dissemination of metastatic lesions was widespread in old bigenic mice we did not detect IGF-1(des) in poorly differentiated primary tumors or metastatic lesions.
1 context sentence(design, population, supporting numbers)
Summary · context
To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1(des) in prostate epithelial cells.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1802613405
06AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
In the transgenic mouse study, endogenous IGF-1 expression was reduced independently of age.
In plain wordsIn mice with the altered gene, natural IGF-1 expression was lower regardless of age.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
DecreaseEndogenous IGF-1 expression
Study
mousen: not reported in source
PB-Des transgenic mice
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Expression of endogenous IGF-1 and levels of P-Akt and P-Erk were reduced independent of age.
1 context sentence(design, population, supporting numbers)
Summary · context
To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1(des) in prostate epithelial cells.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1802613406
07AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
In the transgenic mouse study, P-Akt levels were reduced independently of age.
In plain wordsIn mice with the altered gene, P-Akt levels were lower regardless of age.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
DecreaseP-Akt levels
Study
mousen: not reported in source
PB-Des transgenic mice
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
Expression of endogenous IGF-1 and levels of P-Akt and P-Erk were reduced independent of age.
1 context sentence(design, population, supporting numbers)
Summary · context
To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1(des) in prostate epithelial cells.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1802613407
08AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
In the transgenic mouse study, P-Erk levels were reduced independently of age.
In plain wordsIn mice with the altered gene, P-Erk levels were lower regardless of age.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
DecreaseP-Erk levels
Study
mousen: not reported in source
PB-Des transgenic mice
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
Expression of endogenous IGF-1 and levels of P-Akt and P-Erk were reduced independent of age.
1 context sentence(design, population, supporting numbers)
Summary · context
To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1(des) in prostate epithelial cells.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1802613408
09AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Mechanism
In old bigenic mice, metastatic lesions showed widespread dissemination.
In plain wordsIn old mice with both genetic alterations, cancer spread was widespread.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
Direction not reportedDissemination of metastatic lesions in old bigenic mice
Study
mousen: not reported in source
Old bigenic mice from crossing PB-Des mice with a prostate cancer model
Outcome group
Tumor growth · Cancer
Source sentences
Summary
While dissemination of metastatic lesions was widespread in old bigenic mice we did not detect IGF-1(des) in poorly differentiated primary tumors or metastatic lesions.
2 context sentences(design, population, supporting numbers)
Summary · context
To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1(des) in prostate epithelial cells.
Summary · context
Remarkably, crossing the PB-Des mice to an established model of prostate cancer delayed progression of organ-confined tumors and emergence of metastatic lesions in young mice.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-1802613409

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 2
21 Oct 2026, 13:52 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.